Eneficial effects in many disease models. Having said that, most mammalian cells secret small quantity of EV, that is a limitation for development of therapeutics. Hence, the subsequent generation of EV-mimetic vesicles developed by serial extrusion of cells produces larger quantity of vesicles, and could possibly be less difficult to scale up for therapeutic developments. Within this study we aimed to test the efficacy of EV-mimetic vesicles derived from human adipose-derived stem cells (hASCs) on rat osteoarthritis (OA) model. Techniques: hASC-derived EV-mimetic vesicles (CDV) have been created by serial extrusions of cells by way of filters. The CDVs have been characterized by transmission electron microscopy (TEM), nanoparticle evaluation program (NTA), and western blot and flow cytometry. CDVs were injected in to the joints inside a MIA-induced osteoarthritis (OA) rat model. Improvement of pain just after CDV injections was assessed by paw withdrawal threshold and weight bearing, whereas the joint destruction was evaluated by histology. We also estimated the effects of CDV on proliferation and migration of human chondrocytes in vitro by cell-counting and scratch assays. Final results: The CDV were 5050 nm in diameter and TLR4 supplier carried various EV-associated tetraspanins (CD63, CD9, CD81). CDV-treated OA mice had lowered paw withdrawal and was more weight bearing 17 days following remedy than PBS-treated. Additional, histology showed decreased joint defects at 24 days. CDV-treated OA 5-HT4 Receptor Inhibitor list models displayed substantial improvement in pawJOURNAL OF EXTRACELLULAR VESICLESwithdrawal behaviour and weight bearing evaluation. Similarly, chondrocyte migration and proliferation had been enhanced by CDV inside a dose-dependent manner. Summary/Conclusion: This study demonstrates for the initial time the efficacy of hASC EV-mimetic vesicles in OA model. Most interestingly we’ve confirmed that hASC EV-mimetic vesicles can strengthen discomfort and regenerate defected cartilage. These final results support the notion that a prospective application of hASC EVmimetic is osteoarthritis, by providing CDV locally into affected joints.Funding: This project is sponsored by NIH grant R01DE027404 and the Osteology Foundation Advanced Researcher award.PF08.Exosomes secreted through chondrogenic differentiation of human adipose-derived stem cells for osteoarthritis therapy Ye eun Yuna, Woo Sung Kima, Hyun-A Parkb, Su Yeon Kimb and Yong Woo Choc Department of Chemical Engineering, Hanyang University, Ansan, Republic of Korea; bExostemtech,Inc., Ansan, Republic of Korea; cHanyang University, Ansan, Republic of KoreaaPF08.All-natural and synthetic biomaterial mediated delivery of Mesenchymal Stem Cell derived exosomes Chun-Chieh Huanga, Miya Kanazawab, Praveen Gajendrareddyc and Sriram Ravindranaa University of Illinois at Chicago, Chicago, IL, USA; bUIC College of Dentistry, Oral Biology, Chicago, IL, USA; cUniversity of Illinois, Chicago, Chicago, IL, USAIntroduction: Mesenchymal stem cell (MSC) derived exosomes are versatile agents that possess immunomodulatory and regenerative properties. Even so, systemic delivery of organic or engineered MSC exosomes lacks site-specificity and may trigger ectopic effects. As a result, biomaterial-mediated site-specific delivery of exosomes is very important. As exosomal membranes are subsets on the plasma membrane. We hypothesized that MSC exosomes can bound to extracellular matrix proteins plus the house may be utilised as a delivery strategy. Techniques: To test this hypothesis, we evaluated the binding and delivery kinetics of MSC exosomes to a.